IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach - PubMed (original) (raw)
Clinical Trial
. 1998 Feb 15;101(4):783-94.
doi: 10.1172/JCI1476.
Affiliations
- PMID: 9466973
- PMCID: PMC508626
- DOI: 10.1172/JCI1476
Clinical Trial
IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach
K Asadullah et al. J Clin Invest. 1998.
Abstract
Overexpression of proinflammatory, type 1 cytokines has been demonstrated in psoriasis and is believed to be of pathophysiological importance. IL-10 is a type 2 cytokine with major impact on immunoregulation, since it inhibits type 1/proinflammatory cytokine formation. Therefore, we investigated its role in psoriasis. We found a relative deficiency in cutaneous IL-10 mRNA expression compared with other inflammatory dermatoses. Interestingly, patients during established antipsoriatic therapy showed higher IL-10 mRNA expression of peripheral blood mononuclear cells than patients before therapy. This suggested that IL-10 may have antipsoriatic capacity. Therefore, we performed a phase 2 pilot trial with subcutaneous IL-10 administration (8 microg/kg/d) over 24 d in three patients. Clinical efficiency measured by objective and subjective parameters was found. Immunosuppressive effects (depressed monocytic HLA-DR expression, TNF-alpha and IL-12 secretion capacity, IL-12 plasma levels, and responsiveness to recall antigens) as well as a shift toward a type 2 cytokine pattern (increasing proportion of IL-4, IL-5, and IL-10 producing T cells, selective increase in IgE serum levels) were observed. Remarkably, IL-10 administration also enhanced the intracutaneous IL-10 mRNA expression. Our investigations demonstrate the major importance of IL-10 in psoriasis and show that IL-10 administration represents a new therapeutic approach. This is the first report on IL-10 therapy for cutaneous disorders.
Similar articles
- Comprehensive biomarker monitoring in cytokine therapy: heterogeneous, time-dependent, and persisting immune effects of interleukin-10 application in psoriasis.
Döcke WD, Asadullah K, Belbe G, Ebeling M, Höflich C, Friedrich M, Sterry W, Volk HD. Döcke WD, et al. J Leukoc Biol. 2009 Mar;85(3):582-93. doi: 10.1189/jlb.0408249. Epub 2008 Nov 26. J Leukoc Biol. 2009. PMID: 19038787 Clinical Trial. - The treatment of psoriasis with IL-10: rationale and review of the first clinical trials.
Asadullah K, Döcke WD, Sabat RV, Volk HD, Sterry W. Asadullah K, et al. Expert Opin Investig Drugs. 2000 Jan;9(1):95-102. doi: 10.1517/13543784.9.1.95. Expert Opin Investig Drugs. 2000. PMID: 11060663 Review. - Demonstration and functional analysis of IL-10 receptors in human epidermal cells: decreased expression in psoriatic skin, down-modulation by IL-8, and up-regulation by an antipsoriatic glucocorticosteroid in normal cultured keratinocytes.
Michel G, Mirmohammadsadegh A, Olasz E, Jarzebska-Deussen B, Müschen A, Kemény L, Abts HF, Ruzicka T. Michel G, et al. J Immunol. 1997 Dec 15;159(12):6291-7. J Immunol. 1997. PMID: 9550434 - Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-alpha and interleukin-6 in type 2 diabetic patients.
Navarro JF, Mora C, Gómez M, Muros M, López-Aguilar C, García J. Navarro JF, et al. Nephrol Dial Transplant. 2008 Mar;23(3):919-26. doi: 10.1093/ndt/gfm674. Epub 2007 Oct 2. Nephrol Dial Transplant. 2008. PMID: 17911088 - [Cytokines in children with immunodeficiencies].
Kowalczyk D. Kowalczyk D. Folia Med Cracov. 1999;40(1-2):5-97. Folia Med Cracov. 1999. PMID: 10909468 Review. Polish.
Cited by
- A mathematical insight to control the disease psoriasis using mesenchymal stem cell transplantation with a biologic inhibitor.
Kushary S, Cao X, Ghosh T, Roy PK. Kushary S, et al. Sci Rep. 2024 Sep 19;14(1):21897. doi: 10.1038/s41598-024-71251-3. Sci Rep. 2024. PMID: 39300232 Free PMC article. - Cytokine profile in the saliva of patients with active psoriasis revealed significant upregulation of TNF-α, IFN-γ, IL-2 and downregulation of IL-10.
Sharma RK, Sharma MR, Mahendra A, Sood S, Kumar A, Sharma AK. Sharma RK, et al. Arch Dermatol Res. 2024 May 29;316(6):289. doi: 10.1007/s00403-024-02981-7. Arch Dermatol Res. 2024. PMID: 38809371 No abstract available. - Review: A Contemporary, Multifaced Insight into Psoriasis Pathogenesis.
Dascălu RC, Bărbulescu AL, Stoica LE, Dinescu ȘC, Biță CE, Popoviciu HV, Ionescu RA, Vreju FA. Dascălu RC, et al. J Pers Med. 2024 May 16;14(5):535. doi: 10.3390/jpm14050535. J Pers Med. 2024. PMID: 38793117 Free PMC article. Review. - Obesity-induced dysregulation of skin-resident PPARγ+ Treg cells promotes IL-17A-mediated psoriatic inflammation.
Sivasami P, Elkins C, Diaz-Saldana PP, Goss K, Peng A, Hamersky M 4th, Bae J, Xu M, Pollack BP, Horwitz EM, Scharer CD, Seldin L, Li C. Sivasami P, et al. Immunity. 2023 Aug 8;56(8):1844-1861.e6. doi: 10.1016/j.immuni.2023.06.021. Epub 2023 Jul 20. Immunity. 2023. PMID: 37478855 Free PMC article. - Low-Intensity Physical Exercise Decreases Inflammation and Joint Damage in the Preclinical Phase of a Rheumatoid Arthritis Murine Model.
González-Chávez SA, López-Loeza SM, Acosta-Jiménez S, Cuevas-Martínez R, Pacheco-Silva C, Chaparro-Barrera E, Pacheco-Tena C. González-Chávez SA, et al. Biomolecules. 2023 Mar 7;13(3):488. doi: 10.3390/biom13030488. Biomolecules. 2023. PMID: 36979423 Free PMC article.
References
- Dermatologica. 1978;157(4):238-44 - PubMed
- Gastroenterology. 1997 Aug;113(2):383-9 - PubMed
- J Am Acad Dermatol. 1986 Nov;15(5 Pt 1):1007-22 - PubMed
- J Invest Dermatol. 1990 Jun;94(6 Suppl):135S-140S - PubMed
- J Invest Dermatol. 1991 Mar;96(3):376-82 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials